NIKKEI 225
28,249.24 +73.37 (+0.26%) HANG SENG
20,045.77 -156.17 (-0.77%) CRUDE OIL
90.05 +1.04 (+1.17%) GOLD FUTURES
1,804.00 +12.80 (+0.71%) DOW
32,848.98 +45.51 (+0.14%) BTC-GBP
19,830.52 +503.85 (+2.61%)
Orchard Therapeutics plc (ORTX)
| Previous close | 0.5770 |
| Open | 0.5800 |
| Bid | 0.5900 x 1400 |
| Ask | 0.6000 x 3100 |
| Day's range | 0.5790 - 0.6200 |
| 52-week range | 0.4100 - 3.1800 |
| Volume | |
| Avg. volume | 903,870 |
| Market cap | 74.659M |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2120 |
| Earnings date | 28 Feb 2022 - 04 Mar 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.67 |
- Globe Newswire
Orchard Therapeutics Reports Second Quarter 2022 Financial Results and Reviews Recent Business Highlights
Additional Libmeldy® reimbursement discussions advancing across Europe with product sales totaling $3.1M in Q2 and $8.2M YTD OTL-200 U.S. BLA filing for MLD on track for late 2022 / early 2023 Seven abstracts accepted at SSIEM highlight potential of HSC gene therapy platform to address difficult-to-treat neurodegenerative disorders Ended Q2 with $170.9M of cash and investments and runway into 2024; R&D expenses in Q2 declined 22% from the prior quarter BOSTON and LONDON, Aug. 04, 2022 (GLOBE NEW
- Globe Newswire
Orchard Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Commercial Progress
Product sales for Libmeldy totaled $5.1M for the first two commercial patients treated in Q1 2022 Libmeldy® access and reimbursement expanding with agreements now signed in three major European markets recognizing its clinical value OTL-200 U.S. BLA filing for MLD on track for late 2022 / early 2023 Seven upcoming presentations at ASGCT highlight application of HSC approach including clinical and research programs Cash and investments of approximately $200M provide runway into 2024 BOSTON and LO
- Globe Newswire
Orchard Therapeutics Announces Presentations at ASGCT 2022 Showcasing Potential of HSC Gene Therapy in Neurodegenerative Disorders and Beyond
BOSTON and LONDON, May 10, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today outlined seven presentations from across its platform to be featured at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting taking place May 16-19 in Washington, D.C. Featured presentations include updated results on the OTL-203 clinical program for mucopolysaccharidosis type I Hurler syndrome (MPS-IH), as well as several accepted abstracts highlighting
